Spotlight On
β Is the risk overlooked in infants and children?
Latest in Spotlight On
We may never have answers to some questions, expert says
It can look like other movement disorders, but there are key differences
Adoptive cell therapy, bispecific antibodies, novel immunotherapies among numerous strategies
Treatment with tocilizumab and steroids is standard, but new therapies are emerging
Adoptive cell therapy, bispecific antibodies, novel immunotherapies among numerous strategies
Treatment with tocilizumab and steroids is standard, but new therapies are emerging
More in Spotlight On
Until 2017, no FDA approved options existed for serious side effect of dopamine-blocking drugs
Clinicians need to rely on prescribing practices that minimize risk of development, says expert
With results that matter for patients, the mandate for testing is growing
Long-term treatment can present significant challenges
For high-risk patients, classic "watch and wait" may cede to early therapy
PCPs are "perfectly situated" to identify initial thinking changes of patients, expert says
HER2 blockade, PARP inhibitors, and other novel strategies
Not all patients are candidates for delandistrogene moxeparvovec
Emerging targets and treatment pathways in multiple myeloma
Young MS patients are at risk of irreversible disability accrual
Other JAK inhibitors, combinations, and novel therapies offer more hope for patients
Molecular testing is beginning to make a difference for patients
